Ascelia: Type A Meeting decides the path - Redeye

Redeye returns with an update following the CRL and additional consideration, where we lower the likelihood of approval, include an assumed rights issue, and a later deal and launch. We cut our Fair Value, which also takes peer valuation into account, to SEK1 per share - which screens fairly valued.

Länk till analysen i sin helhet: https://www.redeye.se/research/1177671/ascelia-type-a-meeting-decides-the-path?utm_source=finwire&utm_medium=RSS